Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
VISA‐A (score 0 to 100; 100 = no problems) After 3 months (6 to 12 months) · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
Summary of findings: Injection therapies showed no clear difference in VISA‐A (score 0 to 100; 100 = no problems) At 6 weeks compared with placebo or no injection control (low certainty).
3 findings from 1 review
MD 0.79
5 studies · 200 participants
Low
no estimate extracted
5 studies · 189 participants
Low
MD 0.14
3 studies · 132 participants
Low
Adverse events At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes adverse events At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Pain (VAS; score 0 to 100; 0 = no pain) · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes pain (VAS; score 0 to 100; 0 = no pain) compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Return to sports At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes return to sports At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Patient satisfaction Number of satisfied patients · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes patient satisfaction (number of participants satisfied with their… compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Patient or caregiver behaviours/actions · Adultsa
1 finding from 1 review
Health professional outcomes · Adultsa
1 finding from 1 review
Harms · Adultsa
1 finding from 1 review
Patient or caregiver understanding and support · Adultsa
1 finding from 1 review
Health service outcome: uptake of preventive screening · Adultsa
1 finding from 1 review
Health professional outcomes · Adultsa
1 finding from 1 review
Harms · Adultsa
1 finding from 1 review
Patient or caregiver behaviours/actions · Adultsa
1 finding from 1 review
Participants' health status and well‐being · Adultsa
1 finding from 1 review
Patient or caregiver understanding and support · Adultsa
1 finding from 1 review